|
|
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical Pharmaceutical segment is involved in the manufacturing and sale of therapeutic drugs for liver disease under the name of Godex, as well as the treatment of autoimmune diseases under the name of Remsima. The Other segment manufactures and sells other generic drugs. The Company distributes its products within the domestic market and to overseas markets.
Number of employees : 2 111 people.
|
|
|
| 2018 | 2019 | Delta | | KRW (in Million) | % | KRW (in Million) | % | | Biopharmaceuticals | 861,884 | 87.8% | 981,870 | 87% | +13.92% | | Chemical Drugs | 139,471 | 14.2% | 172,683 | 15.3% | +23.81% | | Other | 7,701 | 0.8% | 4,271 | 0.4% | -44.54% |
|
|
|
| 2018 | 2019 | Delta | | KRW (in Million) | % | KRW (in Million) | % | | South Korea | 890,686 | 90.7% | 1,017,470 | 90.2% | +14.23% | | Overseas | 91,389 | 9.3% | 110,988 | 9.8% | +21.45% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
134,997,805 |
92,245,967 |
68.3% |
1,212,915 |
0.9% |
68.3% |
|
|
|
| Name | Equities | % | | Jung-Jin Seo | 29,884,606 |
22.1% | | National Pension Service of Korea | 12,363,020 |
9.16% | | Temasek Holdings Pte Ltd. (Investment Management) | 10,100,468 |
7.48% | | The Vanguard Group, Inc. | 3,017,396 |
2.24% | | BlackRock Fund Advisors | 2,105,390 |
1.56% | | Baillie Gifford & Co. | 1,810,384 |
1.34% | | Celltrion, Inc. | 1,188,159 |
0.88% | | Norges Bank Investment Management | 1,183,627 |
0.88% | | Mirae Asset Global Investments Co., Ltd. | 983,076 |
0.73% | | Celltrion Inc. Employee Stock Ownership ASSN. | 765,634 |
0.57% |
|
|
|
| Name | Equities | % | Valuation |
| Celltrion Pharm Inc (A068760) | 19,682,190 | 55.0% | 1,887,214,388 USD | | Celltrion, Inc. (A068270) | 1,188,159 | 0.88% | 252,354,207 USD | | Biotoxtech Co Ltd (A086040) | 1,631,134 | 11.2% | 15,237,532 USD |
|
| Company contact information |
|
Celltrion, Inc. 23 Academy-ro Yeonsu-gu Inchon, Incheon 22014 Phone : +82.32.850.5000 Fax : +82.32.850.5040 Web : http://www.celltrion.com |
|
|
|
Investors swamp IPO for K-Pop band BTS management label, prices at top of range |
Sector Biotechnology & Medical Research - NEC
| | 1st jan. | Capitalization (M$) |
 |
 | CELLTRION, INC. | 87.85% | 41 539 |
| | | |
|
 | MODERNA, INC. | 620.91% | 60 441 |
 | LONZA GROUP AG | 61.27% | 46 692 |
| IQVIA HOLDINGS INC. | 9.37% | 32 400 |
| SEAGEN INC. | 55.27% | 30 708 |
| IMMUNOMEDICS, INC. | 315.22% | 20 324 |
| INCYTE CORPORATION | -3.18% | 18 514 |
| ALNYLAM PHARMACEUTICALS, INC. | 14.85% | 15 093 |
 | HANGZHOU TIGERMED CONSULTING CO.,LTD | 80.52% | 15 061 |
| PPD, INC. | 0.00% | 12 238 |
| BIO-TECHNE CORPORATION | 38.92% | 11 711 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 50.67% | 11 666 |
| PHARMARON BEIJING CO., LTD. | 81.61% | 11 024 |
| QIAGEN N.V. | 42.78% | 11 009 |
| ICON PUBLIC LIMITED COMPANY | 14.64% | 10 285 |
| ACADIA PHARMACEUTICALS INC. | 32.75% | 9 008 |
| CRISPR THERAPEUTICS AG | 108.39% | 8 967 |
 | GALAPAGOS NV | -43.51% | 8 055 |
| PRA HEALTH SCIENCES, INC. | 0.94% | 7 198 |
| NOVAVAX, INC. | 3,405.03% | 7 134 |
| IONIS PHARMACEUTICALS, INC. | -15.38% | 7 065 |
Connections : Celltrion, Inc. |
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
